Decuyper I I, Mangodt E A, Van Gasse A L, Claesen K, Uyttebroek A, Faber M, Sabato V, Bridts C H, Mertens C, Hagendorens M M, De Clerck L S, Ebo Didier G
Laboratory of Immunology, Department of Immunology, Allergology, Rheumatology, Faculty of Medicine and Health Science, Antwerp University Hospital, University of Antwerp, CDE T5.95, Universiteitsplein 1, 2610, Antwerp, Belgium.
Department of Paediatrics, Faculty of Medicine and Health Science, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.
Drugs R D. 2017 Jun;17(2):265-278. doi: 10.1007/s40268-017-0176-x.
For most physicians, quantification of drug-specific immunoglobulin E (drug-sIgE) antibodies constitutes the primary in vitro measure to document immediate drug hypersensitivity reactions (IDHR). Unfortunately, this is often insufficient to correctly identify patients with IgE-mediated IDHR and impossible for non-IgE-mediated IDHR that result from alternative routes of basophil and mast cell activation. In these difficult cases, diagnosis might benefit from cellular tests such as basophil activation tests (BAT).
The aim was to review the potential and limitations of quantification of sIgE and BAT in diagnosing IDHR. The utility of quantification of serum tryptase is discussed.
A literature search was conducted using the key words allergy, basophil activation, CD63, CD203c, diagnosis, drugs, hypersensitivity, flow cytometry, specific IgE antibodies; this was complemented by the authors' own experience.
The drugs that have been most studied with both techniques are β-lactam antibiotics and curarizing neuromuscular blocking agents (NMBA). For sIgE morphine, data are available on the value of this test as a biomarker for sensitization to substituted ammonium structures that constitute the major epitope of NMBA, especially rocuronium and suxamethonium. For the BAT, there are also data on non-steroidal anti-inflammatory drugs (NSAIDs) and iodinated radiocontrast media. For β-lactam antibiotics, sensitivity and specificity of sIgE varies between 0 and 85% and 52 and 100%, respectively. For NMBA, sensitivity and specificity varies between 38.5 and 92% and 85.7 and 100%, respectively. Specific IgE to morphine should not be used in isolation to diagnose IDHR to NMBA nor opiates. For the BAT, sensitivity generally varies between 50 and 60%, whereas specificity attains 80%, except for quinolones and NSAIDs.
Although drug-sIgE assays and BAT can provide useful information in the diagnosis of IDHR, their predictive value is not absolute. Large-scale collaborative studies are mandatory to harmonize and optimize test protocols and to establish drug-specific decision thresholds.
对于大多数医生而言,药物特异性免疫球蛋白E(药物特异性IgE)抗体的定量检测是记录速发型药物过敏反应(IDHR)的主要体外检测方法。不幸的是,这往往不足以正确识别IgE介导的IDHR患者,对于由嗜碱性粒细胞和肥大细胞激活的替代途径导致的非IgE介导的IDHR则无法检测。在这些疑难病例中,细胞检测如嗜碱性粒细胞激活试验(BAT)可能有助于诊断。
旨在综述sIgE定量检测和BAT在诊断IDHR中的潜力和局限性。并讨论血清类胰蛋白酶定量检测的实用性。
使用关键词过敏、嗜碱性粒细胞激活、CD63、CD203c、诊断、药物、过敏反应、流式细胞术、特异性IgE抗体进行文献检索;作者自身经验也作为补充。
两种技术研究最多的药物是β-内酰胺类抗生素和箭毒样神经肌肉阻滞剂(NMBA)。对于sIgE检测吗啡,有关于该检测作为对构成NMBA主要表位的取代铵结构致敏的生物标志物价值的数据,尤其是罗库溴铵和琥珀胆碱。对于BAT,也有关于非甾体抗炎药(NSAIDs)和碘化造影剂的数据。对于β-内酰胺类抗生素,sIgE的敏感性和特异性分别在0%至85%和52%至100%之间变化。对于NMBA,敏感性和特异性分别在38.5%至92%和85.7%至100%之间变化。不应单独使用吗啡特异性IgE来诊断对NMBA或阿片类药物的IDHR。对于BAT,敏感性一般在50%至60%之间变化,而特异性可达80%,喹诺酮类和NSAIDs除外。
尽管药物特异性IgE检测和BAT在IDHR诊断中可提供有用信息,但其预测价值并非绝对。必须开展大规模协作研究以统一和优化检测方案,并建立药物特异性决策阈值。